HIV infection has a significant impact on the natural history of chronic hepatitis B virus (HBV)
infection, with increased levels of HBV DNA, accelerated progression of liver disease and …

Hepatitis due to hepatitis B virus (HBV) reactivation can be serious and potentially fatal, but
is preventable. HBV reactivation is most commonly reported in patients receiving …

Hepatitis B virus (HBV) affects approximately two billion people worldwide and more than
240 million people in the world are currently chronic carrier that could develop serious …

Hepatitis B virus (HBV) has a worldwide distribution and is endemic in many populations.
Due to its unique life cycle which requires an error-prone reverse transcriptase for …

Hepatitis B virus (HBV) reactivation occurs as a major complication of immunosuppressive
therapy among persons who have recovered from acute hepatitis and those who have …

Hepatitis B virus (HBV) infection is a major public health problem in many countries, with
nearly 300 million people worldwide carrying HBV chronic infection and over 1 million …

Ocrelizumab is an anti-CD20 monoclonal antibody for the treatment of multiple sclerosis
(MS) that is closely related to rituximab. We describe a case of hepatitis B virus (HBV) …

Although there is no effective cure for chronic hepatitis B virus (HBV) infection, antibodies
are protective and correlate with recovery from infection. To examine the human antibody …

Hepatitis B virus reactivation (HBV-R), which can lead to HBV-related morbidity and
mortality, is a common and well-known complication that occurs during the treatment of non …

Rituximab is currently used not only in the treatment of B-cell lymphoma but also for various
other diseases, including autoimmune diseases, post-transplant graft vs host disease, and …